Compare PCVX & BIRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCVX | BIRK |
|---|---|---|
| Founded | 2013 | 1774 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 5.6B |
| IPO Year | 2020 | 2023 |
| Metric | PCVX | BIRK |
|---|---|---|
| Price | $59.23 | $31.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | ★ $88.25 | $61.43 |
| AVG Volume (30 Days) | 927.4K | ★ 3.1M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $13.71 |
| Revenue Next Year | N/A | $14.30 |
| P/E Ratio | ★ N/A | $17.48 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $30.81 | $31.33 |
| 52 Week High | $65.00 | $50.73 |
| Indicator | PCVX | BIRK |
|---|---|---|
| Relative Strength Index (RSI) | 47.74 | 26.82 |
| Support Level | $58.51 | N/A |
| Resistance Level | $63.39 | $42.91 |
| Average True Range (ATR) | 2.10 | 1.30 |
| MACD | -0.39 | -0.27 |
| Stochastic Oscillator | 10.69 | 1.88 |
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
Birkenstock is a German footwear brand known for comfort-focused, timeless designs, with 76% of 2022 sales coming from its top five iconic models. Products are made in Europe using sustainable, mostly locally sourced materials. The brand combines orthopedic function with everyday style, appealing to a broad audience. The Americas account for 52% of sales, EMEA 37%, with the remainder coming from Asia-Pacific, which has also the higher future growth expectations.